Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
Annals of Neurology · 2024-04 · 95 (4) · 720-732
DOI: 10.1002/ana.26858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 13.01.2024. Verfasst von Ankelien Duchow und 45 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Neuromyelitis Optica. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BMBF, NEMOS e.V., Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Objective
To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein‐antibody‐associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.
Methods
We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).
Results
We included 483 patients: 298 AQP4‐IgG + NMOSD, 52 AQP4‐IgG − /MOG‐IgG − NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4‐IgG+ NMOSD 7.7 (95% CI 6.6–9.6) years, AQP4‐IgG − /MOG‐IgG − NMOSD 8.7 ) years, MOGAD 14.1 (95% CI 10.4–27.6) years; EDSS 4: 11.9 (95% CI 9.7–14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5–32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4‐IgG + NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.
Interpretation
AQP4‐IgG + NMOSD, AQP4‐IgG − /MOG‐IgG − NMOSD, and MOGAD patients show distinctive relapse‐associated disability progression, with MOGAD having a less severe disease course. Investigator‐initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD. ANN NEUROL 2024;95:720–732
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
- Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
- Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- Department of Neurology, University of Regensburg, Regensburg, Germany.
ORCID-Profile: Tim Friede, Daniel Engels, Matthias Grothe, Tania Kümpfel, Lisa Lohmann, Marius Ringelstein, Makbule Senel, Clemens Warnke, Martin S Weber, Friedemann Paul, Vivien Häußler
Förderung
- BMBF
- NEMOS e.V.
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Duchow, A., Bellmann-Strobl, J., Friede, T., Aktas, O., Angstwurm, K., Ayzenberg, I., Berthele, A., Dawin, E., Engels, D., Fischer, K., Flaskamp, M., Giglhuber, K., Grothe, M., Havla, J., Hümmert, M. W., Jarius, S., Kaste, M., Kern, P., Kleiter, I., …, & Neuromyelitis Optica Study Group (NEMOS) (2024). Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD. Annals of Neurology, 95(4), 720-732. https://doi.org/10.1002/ana.26858
Vancouver
Duchow A, Bellmann-Strobl J, Friede T, Aktas O, Angstwurm K, Ayzenberg I, et al. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD. Annals of Neurology. 2024;95(4):720-732. doi:10.1002/ana.26858
BibTeX
@article{Duchow2024,
author = {Duchow, Ankelien and Bellmann-Strobl, Judith and Friede, Tim and Aktas, Orhan and Angstwurm, Klemens and Ayzenberg, Ilya and Berthele, Achim and Dawin, Eva and Engels, Daniel and Fischer, Katinka and Flaskamp, Martina and Giglhuber, Katrin and Grothe, Matthias and Havla, Joachim and Hümmert, Martin W and Jarius, Sven and Kaste, Matthias and Kern, Peter and Kleiter, Ingo and Klotz, Luisa and Korporal-Kuhnke, Mirjam and Kraemer, Markus and Krumbholz, Markus and Kümpfel, Tania and Lohmann, Lisa and Ringelstein, Marius and Rommer, Paulus and Schindler, Patrick and Schubert, Charlotte and Schwake, Carolin and Senel, Makbule and Then Bergh, Florian and Tkachenko, Daria and Tumani, Hayrettin and Trebst, Corinna and Vardakas, Ioannis and Walter, Annette and Warnke, Clemens and Weber, Martin S and Wickel, Jonathan and Wildemann, Brigitte and Winkelmann, Alexander and Paul, Friedemann and Stellmann, Jan-Patrick and Häußler, Vivien and Neuromyelitis Optica Study Group (NEMOS), Neuromyelitis Optica Study Group (NEMOS)},
title = {Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD},
journal = {Annals of Neurology},
year = {2024},
volume = {95},
number = {4},
pages = {720--732},
doi = {10.1002/ana.26858}
}
EUVIMED